scholarly journals Assessing whether early attention of very preterm infants can be improved by an omega-3 long-chain polyunsaturated fatty acid intervention: a follow-up of a randomised controlled trial

BMJ Open ◽  
2018 ◽  
Vol 8 (5) ◽  
pp. e020043 ◽  
Author(s):  
Jacqueline F Gould ◽  
John Colombo ◽  
Carmel T Collins ◽  
Maria Makrides ◽  
Erandi Hewawasam ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
Chain Polyunsaturated Fatty Acid ◽  
Omega 3 ◽  
Very Preterm Infants ◽  
Very Preterm ◽  
Randomised Controlled ◽  
Long Chain

scholarly journals Protocol for assessing whether cognition of preterm infants <29 weeks’ gestation can be improved by an intervention with the omega-3 long-chain polyunsaturated fatty acid docosahexaenoic acid (DHA): a follow-up of a randomised controlled trial

BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e041597
Author(s):  
Jacqueline F Gould ◽  
Maria Makrides ◽  
Thomas R Sullivan ◽  
Peter J Anderson ◽  
Robert A Gibson ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Randomised Controlled Trial ◽  
Docosahexaenoic Acid ◽  
Controlled Trial ◽  
Fetal Brain ◽  
Growth Spurt ◽  
Chain Polyunsaturated Fatty Acid ◽  
Omega 3 ◽  
Randomised Controlled

IntroductionDocosahexaenoic acid (DHA) is an omega-3 (n-3) fatty acid that accumulates into neural tissue during the last trimester of pregnancy, as the fetal brain is undergoing a growth spurt. Infants born <29 weeks’ gestation are deprived the normal in utero supply of DHA during this period of rapid brain development. Insufficient dietary DHA postnatally may contribute to the cognitive impairments common among this population. This follow-up of the N-3 fatty acids for improvement in respiratory outcomes (N3RO) randomised controlled trial aims to determine if enteral DHA supplementation in infants born <29 weeks’ gestation during the first months of life improves cognitive development at 5 years of age corrected for prematurity.Methods and analysisN3RO was a randomised controlled trial of enteral DHA supplementation (60 mg/kg/day) or a control emulsion (without DHA) in 1273 infants born <29 weeks’ gestation to determine the effect on bronchopulmonary dysplasia (BPD). We showed that DHA supplementation did not reduce the risk of BPD and may have increased the risk.In this follow-up at 5 years’ corrected age, a predefined subset (n=655) of children from five Australian sites will be invited to attend a cognitive assessment with a psychologist. Children will be administered the Wechsler Preschool and Primary Scale of Intelligence (fourth edition) and a measure of inhibitory control (fruit stroop), while height, weight and head circumference will be measured.The primary outcome is full-scale IQ. To ensure 90% power, a minimum of 592 children are needed to detect a four-point difference in IQ between the groups.Research personnel and families remain blinded to group assignment.Ethics and disseminationThe Women’s and Children Health Network Human Research Ethics Committee reviewed and approved the study (HREC/17/WCHN/187). Caregivers will give informed consent prior to taking part in this follow-up study. Findings of this study will be disseminated through peer-reviewed publications and conference presentations.Trial registration numberACTRN12612000503820.

scholarly journals No effect ofn-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial

2008 ◽  
Vol 99 (2) ◽  
pp. 421-431 ◽  
Author(s):  
Peter J. Rogers ◽  
Katherine M. Appleton ◽  
David Kessler ◽  
Tim J. Peters ◽  
David Gunnell ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Cognitive Function ◽  
Randomised Controlled Trial ◽  
Depressed Mood ◽  
Controlled Trial ◽  
Chain Polyunsaturated Fatty Acid ◽  
Epa And Dha ◽  
Increased Risk ◽  
Randomised Controlled ◽  
Long Chain

Low dietary intakes of then-3 long-chain PUFA (LCPUFA) EPA and DHA are thought to be associated with increased risk for a variety of adverse outcomes, including some psychiatric disorders. Evidence from observational and intervention studies for a role ofn-3 LCPUFA in depression is mixed, with some support for a benefit of EPA and/or DHA in major depressive illness. The present study was a double-blind randomised controlled trial that evaluated the effects of EPA+DHA supplementation (1·5 g/d) on mood and cognitive function in mild to moderately depressed individuals. Of 218 participants who entered the trial, 190 completed the planned 12 weeks intervention. Compliance, confirmed by plasma fatty acid concentrations, was good, but there was no evidence of a difference between supplemented and placebo groups in the primary outcome – namely, the depression subscale of the Depression Anxiety and Stress Scales at 12 weeks. Mean depression score was 8·4 for the EPA+DHA group and 9·6 for the placebo group, with an adjusted difference of − 1·0 (95 % CI − 2·8, 0·8;P = 0·27). Other measures of mood, mental health and cognitive function, including Beck Depression Inventory score and attentional bias toward threat words, were similarly little affected by the intervention. In conclusion, substantially increasing EPA+DHA intake for 3 months was found not to have beneficial or harmful effects on mood in mild to moderate depression. Adding the present result to a meta-analysis of previous relevant randomised controlled trial results confirmed an overall negligible benefit ofn-3 LCPUFA supplementation for depressed mood.

scholarly journals No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial – reply by Rogers et al.

2008 ◽  
Vol 100 (6) ◽  
pp. 1349-1351 ◽  
Author(s):  
Peter J. Rogers ◽  
Katherine M. Appleton ◽  
David Kessler ◽  
Tim J. Peters ◽  
David Gunnell ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Cognitive Function ◽  
Randomised Controlled Trial ◽  
Depressed Mood ◽  
Controlled Trial ◽  
Chain Polyunsaturated Fatty Acid ◽  
Pufa Supplementation ◽  
Chain Pufa ◽  
Randomised Controlled ◽  
Long Chain

We recently reported a null outcome from a study of n-3 long-chain PUFA supplementation in depressed mood(1).

scholarly journals Enteral Lactoferrin Supplementation for Very Preterm Infants: A Randomised Controlled Trial

2018 ◽  
Author(s):  
James Griffiths ◽  
Paula Jenkins ◽  
Monika Vargova ◽  
Ursula Bowler ◽  
Edmund Juszczak ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Preterm Infants ◽  
Controlled Trial ◽  
Very Preterm Infants ◽  
Very Preterm ◽  
Randomised Controlled
Sign in / Sign up

Export Citation Format

Share Document